|
XELODA
(generic name: capecitabine)
|
 |
|
| |
 |
Reviews |
|
Clin Cancer Res. 2005 Mar 1;11(5):1870-6.
Phase II Evaluation of Docetaxel-Modulated Capecitabine
in Previously Treated Patients with Non-Small Cell Lung Cancer.
Kindwall-Keller T, Otterson GA, Young D, Neki A, Criswell
T, Nuovo G, Soong R, Diasio R, Villalona-Calero MA.
Division
of Hematology/Oncology, Arthur G. James Cancer Hospital and Richard J. Solove
Research Institute.
PURPOSE: Based on the preclinical observation of upregulation of thymidine
phosphorylase, the last enzymatic step in the conversion of capecitabine
to 5-fluorouracil, by docetaxel along with good clinical tolerability of
the combination of docetaxel and capecitabine using an optimized schedule
in a previous phase I trial, we conducted this phase II study of this combination
in patients with refractory or relapsed non-small cell lung cancer (NSCLC).Patients
and Methods: Patients with NSCLC previously treated with at least one platinum-
or paclitaxel-based regimen received docetaxel 36 mg/m(2) on days 1, 8,
and 15 and capecitabine 625 mg/m(2) twice daily on days 5 to 18, every 4
weeks. The primary objective of the study was evaluation of progression-free
survival (PFS) 26 weeks from initiation of treatment.RESULTS: Thirty-six
evaluable patients received 104 cycles of the combination. Severe toxicities
were infrequent with only one patient requiring toxicity-related hospitalization.
The 26-week PFS rate was 25% (95% confidence interval, 12-42) with an intent
to treat median survival and 1-year survival rate of 9.1 months and 37%,
respectively. Among 31 patients with measurable disease (Response Evaluation
Criteria in Solid Tumors criteria), eight (26%; 95% confidence interval,
12-45) achieved partial responses.CONCLUSION: The combination of capecitabine
and weekly docetaxel is well tolerated in previously treated patients with
NSCLC. The relatively high 26-week PFS and 1-year survival, as well as the
high response rate observed, encourages further evaluation of this regimen
in NSCLC, either in randomized trials for refractory patients or as a potential
treatment option for chemotherapy naive patients. |
Zhonghua Zhong Liu Za Zhi. 2004 Dec;26(12):746-8.
[Oxaliplatin plus capecitabine as a second line chemotherapy
for patients with advanced gastric cancer.]
[Article in Chinese]
Qian J, Qin SK, Mei JF,
Chen YX, Shao ZJ, He ZM.
Department of Medical Oncology, PLA Oncology Center, 81st Hospital, Nanjing
210002, China.
OBJECTIVE: To evaluate the effect and toxicity of oxaliplatin combined with
capecitabine (Xeloda) as a second-line chemotherapy regimen for patients
with advanced gastric cancer. METHODS: Twenty-four patients with advanced
gastric cancer who had been treated by multiple chemotherapy regimens presenting
poor responses were allotted. LX regimen (oxaliplatin 85 mg/m(2) in 2-hour
infusion on D1 and D15, capecitabine 1250 mg/m(2)/d divided in two daily
doses given from D1 to D14) was adopted. The cycles were repeated every
28 days. All patients received two or more cycles. RESULTS: All 24 patients
were evaluated after having received 2 to 6 cycles of chemotherapy, totally
92 cycles. The overall response rate was 29.2% (including 2 CR, 5 PR, 10
NC and 7 PD). The time to tumor progression (TTP) was 2 to 18 months (median
5 months), and duration of remission was 4 to 14 months (median 8 months).
The major toxicities were bone marrow suppression and nausea/vomiting. CONCLUSION:
Oxaliplatin combined with capitabine is effective as a secondary line regimen
for patients with advanced gastric cancer. This protocol is active and well
tolerated. Further clinical studies are warranted. |
| Br J Cancer. 2005
Mar 14;92(5):820-6.
A phase I clinical and pharmacokinetic study of capecitabine
(Xeloda((R))) and irinotecan combination therapy (XELIRI) in patients
with metastatic gastrointestinal tumours.
Delord JP, Pierga JY, Dieras V, Bertheault-Cvitkovic
F, Turpin FL, Lokiec F, Lochon I, Chatelut E, Canal P, Guimbaud R, Mery-Mignard
D, Cornen X, Mouri Z, Bugat R.
1Institut Claudius Regaud, 20-24, rue du Pont Saint Pierre, Toulouse 31052,
France.
Capecitabine is a highly active oral fluoropyrimidine that is an attractive
alternative to 5-fluorouracil in colorectal cancer treatment. The current
study, undertaken in 27 patients with gastrointestinal tumours, aimed
to assess the toxicity and potential for significant pharmacokinetic interactions
of a combination regimen incorporating capecitabine with 3-weekly irinotecan
(XELIRI). Irinotecan (200 and 250 mg m(-2)) was administered as a 90-min
infusion on day 1 in combination with escalating capecitabine doses (700-1250
mg m(-2) twice daily) administered on days 2-15 of a 3-week treatment
cycle. Pharmacokinetics were characterised on days 1 and 2 of the first
two cycles. A total of 103 treatment cycles were administered. The principal
dose-limiting toxicities were diarrhoea and neutropenia. Capecitabine
1150 mg m(-2) twice daily with irinotecan 250 mg m(-2) was identified
as the maximum-tolerated dose and capecitabine 1000 mg m(-2) with irinotecan
250 mg m(-2) was identified as the recommended dose for further study.
Analyses confirmed that there were no significant pharmacokinetic interactions
between the two agents. The combination was clinically active, with complete
and partial responses achieved in heavily pretreated patients. This study
indicates that XELIRI is a potentially feasible and clinically active
regimen in patients with advanced gastrointestinal cancer.British Journal
of Cancer (2005) 92, 820-826. doi:10.1038/sj.bjc.6602354 www.bjcancer.com
Published online 1 March 2005. |
| |
|
Drug information |
|
| GENERIC NAME: capecitabine
BRAND NAME: Xeloda
DRUG CLASS AND MECHANISM: Capecitabine is an oral medication
for treating advanced breast cancers that are resistant to combination
therapy with the drugs of choice, paclitaxel (Taxol) and a drug from the
anthracycline family of drugs, for example, doxorubicin (Adriamycin).
Capecitabine is converted by the body to 5-fluorouracil (5-FU), a drug
which has been given intravenously for many years to treat various types
of cancer. It is not surprising, therefore, that capecitabine also has
shown promise in the treatment of colorectal cancer, a type of cancer
which is treated frequently with 5-FU. 5-FU inhibits the production of
both DNA and protein by the cancerous cells that are necessary for the
cells to divide and the cancer to grow in size. Capecitabine was approved
by the FDA in 1998.
PREPARATIONS: Tablets: 150mg and 500mg.
STORAGE: Tablets should be stored at room temperature,
15-30 °C (59-86 °F).
PRESCRIBED FOR: Capecitabine is used for treating women
with breast cancer that is resistant to other more commonly-used drugs.
DOSING: Capecitabine generally is taken twice daily,
with the two doses approximately 12 hours apart. Tablets should be taken
30 minutes after eating. Capecitabine usually is prescribed in repeated
cycles of 3-weeks, with the drug taken for two consecutive weeks followed
by a week without drug. Some patients may need lower or delayed dosing.
As always, the physician's dosing instructions should be followed.
DRUG INTERACTIONS: There are no known drug interactions
with capecitabine.
PREGNANCY: Capecitabine can damage the fetus. It should
not be taken by pregnant women.
NURSING MOTHERS: It is not known whether capecitabine
is secreted into breast milk.
SIDE EFFECTS: The most common side effects with capecitabine
are diarrhea, nausea, vomiting, painful swelling of the mouth, fatigue,
painful rash and swelling of the hands or feet, low white blood cell count
(which can lead to infections), low blood platelet counts (which can lead
to bleeding), and anemia. About one of every three patients who receives
capecitabine has serious side effects, but these side effects usually
are reversible when the drug is stopped or when the dose is lowered. Glossary
content Copyright © 1996-2002 MedicineNet, Inc. All rights reserved.
Caution! Before starting
to take this medicine, it is vital that you should consult your doctor!
Do not use it on your own initiative, without medical advice.
|
| |
|
Order now ! |
|
|
XELODA
Substance: Capecitabine
Manufacturer: Bristol-Myers Squibb
|
|
Dosage |
Packing |
Price |
Pay now |
150 mg |
60 tab |
USD 190.00 |
|
500 mg |
120 tab |
USD 874.00 |
|
|
|
| |
|  
|
|
